Superworth

Vericel price to free cash flow VCEL

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Nov 2, 2026
33.6×
6-year median
92.7×
Against its 6-year history
3rd
percentile: 0 is its lowest day, 100 its highest
6-year range
31.8× to 313×
Peer median
27.6×

Vericel's price to free cash flow is 33.6× as of Nov 2, 2026.

That is below its 6-year median of 92.7×, lower than on 97% of days in the last 6 years.

Over that time it ranged from 31.8× in Sep 2026 to 313× in Feb 2021.

The median for 8 biotech stocks of a similar size is 27.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far33.6×31.8×95.7×
202593.5×89.5×99.9×
2024151×82.1×164×
202389.9×71.6×155×
202290.1×63.4×118×
202184.3×76.5×313×
2020188×68.6×188×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

CompanyPrice to free cash flow
VCELVericel33.6×
ADMAAdma Biologics21.3×
MGTXMeiraGTx85.5×
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
Peer median27.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Vericel

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.